Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
Saved in:
| Title: | Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study |
|---|---|
| Authors: | Vuylsteke, P.1 peter.vuylsteke@cmsenamur.be, Huizing, M.2, Petrakova, K.3, Roylance, R.4, Laing, R.5, Chan, S.6, Abell, F.7, Gendreau, S.8, Rooney, I.9, Apt, D.10, Zhou, J.11, Singel, S.9, Fehrenbacher, L.12 |
| Source: | Annals of Oncology. Nov2016, Vol. 27 Issue 11, p2059-2066. 8p. 1 Diagram, 3 Charts, 1 Graph. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
